Anas Younes, MD is the Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, NY. www.mskcc.org
Dr Younes works with clinical and basic-science scientists to accelerate the translation of recent scientific discoveries into novel treatment strategies, to improve the cure rate and survival of patients with Hodgkin and non-Hodgkin lymphomas.
Dr Younes joined Memorial Sloan Kettering in 2013 with two decades of experience in treating and managing people with lymphoma, and with an extensive background in translational scientific research. He is particularly interested in developing novel targeted therapies and linking them to early biomarkers that can help match patients with the most effective and minimally toxic medicines.
Dr Younes has served as the principal investigator of more than 60 clinical trials in patients with Hodgkin and non-Hodgkin lymphoma, including national and international multi-center studies. He has led the efforts of developing the first FDA-approved targeted drug for the treatment of Hodgkin lymphoma in more than three decades (Brentuximab vedotin).